What is Zacks Small Cap’s Estimate for RANI FY2025 Earnings?

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) – Equities researchers at Zacks Small Cap raised their FY2025 earnings per share (EPS) estimates for Rani Therapeutics in a note issued to investors on Tuesday, April 1st. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earn ($0.74) per share for the year, up from their previous estimate of ($0.89). The consensus estimate for Rani Therapeutics’ current full-year earnings is ($1.01) per share. Zacks Small Cap also issued estimates for Rani Therapeutics’ FY2026 earnings at ($0.64) EPS.

A number of other research firms have also weighed in on RANI. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Rani Therapeutics in a report on Thursday. Canaccord Genuity Group reiterated a “buy” rating and set a $9.00 price target on shares of Rani Therapeutics in a report on Wednesday, February 26th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Rani Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $12.33.

Rani Therapeutics Stock Performance

RANI opened at $1.39 on Thursday. The company has a market cap of $79.63 million, a price-to-earnings ratio of -1.31 and a beta of 0.14. The company’s fifty day moving average price is $1.51 and its two-hundred day moving average price is $1.82. Rani Therapeutics has a 1-year low of $1.20 and a 1-year high of $8.75. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 2.34.

Rani Therapeutics (NASDAQ:RANI) last issued its earnings results on Monday, March 31st. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The firm had revenue of $1.03 million during the quarter.

Hedge Funds Weigh In On Rani Therapeutics

Several institutional investors have recently modified their holdings of the business. Janney Montgomery Scott LLC bought a new position in Rani Therapeutics during the fourth quarter valued at about $37,000. Virtu Financial LLC bought a new stake in shares of Rani Therapeutics during the 4th quarter valued at $62,000. Insigneo Advisory Services LLC bought a new stake in shares of Rani Therapeutics during the fourth quarter valued at about $65,000. Two Sigma Advisers LP purchased a new stake in Rani Therapeutics in the 4th quarter worth approximately $151,000. Finally, Takeda Pharmaceutical Co. Ltd. purchased a new stake in shares of Rani Therapeutics in the fourth quarter worth $278,000. 30.19% of the stock is owned by institutional investors.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.